KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC

被引：6
|
作者：
Rudin, C. [1 ]
Shen, L. [2 ]
Pietanza, M. C. [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
KEYNOTE-604; pembrolizumab; small-cell lung cancer;
D O I：
10.1016/j.jtho.2017.11.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-007
引用
收藏
页码：S2400 / S2400
页数：1
相关论文
共 50 条
  • [31] Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate placebo in extensive-stage small-cell lung cancer: A North Central cancer treatment group study
    Rowland, KM
    Loprinzi, CL
    Shaw, EG
    Maksymiuk, AW
    Kuross, SA
    Jung, SH
    Kugler, JW
    Tschetter, LK
    Ghosh, C
    Schaefer, PL
    Owen, D
    Washburn, JH
    Webb, TA
    Mailliard, JA
    Jett, JR
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 135 - 141
  • [32] KEYNOTE-826: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Tewari, K.
    Caceres, M. V.
    Alexandre, J.
    Monk, B.
    Fehm, T.
    Colombo, N.
    Hasegawa, K.
    Dubot, C.
    Li, J. J.
    Stein, K.
    Keefe, S.
    Shapira-Frommer, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A162 - A162
  • [33] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
    Cortes, J.
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V.
    Pan, W.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
  • [34] Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
    Machiels, Jean-Pascal
    Tao, Yungan
    Licitra, Lisa
    Burtness, Barbara
    Tahara, Makoto
    Rischin, Danny
    Alves, Gustavo
    Lima, Iane Pinto Figueiredo
    Hughes, Brett G. M.
    Pointreau, Yoann
    Aksoy, Sercan
    Laban, Simon
    Greil, Richard
    Burian, Martin
    Hetnal, Marcin
    Delord, Jean-Pierre
    Mesia, Ricard
    Taberna, Miren
    Waldron, John N.
    Simon, Christian
    Gregoire, Vincent
    Harrington, Kevin J.
    Swaby, Ramona F.
    Zhang, Yayan
    Gumuscu, Burak
    Bidadi, Behzad
    Siu, Lillian L.
    LANCET ONCOLOGY, 2024, 25 (05): : 572 - 587
  • [35] Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
    Choueiri, Toni K.
    Ross, Robert W.
    Jacobus, Susanna
    Vaishampayan, Ulka
    Yu, Evan Y.
    Quinn, David I.
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Morrissey, Stephanie C.
    Buckle, Geoffrey C.
    Kim, William Y.
    Petrylak, Daniel P.
    Ryan, Christopher W.
    Eisenberger, Mario A.
    Mortazavi, Amir
    Bubley, Glenn J.
    Taplin, Mary-Ellen
    Rosenberg, Jonathan E.
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 507 - 512
  • [36] A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer
    Choueiri, T. K.
    Vaishampayan, U. N.
    Yu, E. Y.
    Quinn, D. I.
    Hahn, N. M.
    Hutson, T. E.
    Ross, R. W.
    Rosenberg, J. E.
    Jacobus, S. J.
    Kantoff, P. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [37] Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
    Monk, Bradley
    Tewari, Krishnansu
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    De Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Nguyen, Allison Martin
    Monberg, Matthew
    Colombo, Nicoletta
    Lorusso, Domenica
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S18 - S18
  • [38] KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.
    Choueiri, Toni K.
    Quinn, David I.
    Zhang, Tian
    Gurney, Howard
    Doshi, Gurjyot K.
    Cobb, Patrick Wayne
    Parnis, Francis
    Lee, Jae-Lyun
    Park, Se Hoon
    Semenov, Andrey
    Chang, Wayne Yen-Hwa
    Wan, Shuyan M.
    Poehlein, Christian Heinrich
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
    Colombo, N.
    Coleman, R. L.
    Wu, X.
    Kose, F.
    Wenham, R.
    Sebastianelli, A.
    Hasegawa, K.
    Zsiros, E.
    Rouge, T. De La Motte
    Bidzinski, M.
    McNeish, I.
    Sehouli, J.
    Korach, J.
    Debruyne, P. R.
    Kim, J-W.
    De Melo, A. C.
    Peng, X.
    Bogusz, A. M.
    Yamada, K.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2022, 33 : S400 - S401
  • [40] KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
    Shapira-Frommer, Ronnie
    Alexandre, Jerome
    Monk, Bradley
    Fehm, Tanja N.
    Colombo, Nicoletta
    Caceres, Maria V.
    Hasegawa, Kosei
    Dubot, Coraline
    Li, Jerry Jing
    Stein, Karen
    Keefe, Stephen Michael
    Tewari, Krishnansu Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345